agonist
US /'ægənɪst/
・UK /'ægənɪst/
A1
n.NounDrug binding to a receptor to create a reaction
Video subtitles
What is MOUNJARO? How it works and how this Diabetes Drug Became a Weight Loss Game-Changer!
- Unlike Ozempic, which was adapted from lizard spit—yes, lizard spit—Mounjaro was designed from the ground up by Eli Lilly to be a dual receptor agonist.
Unlike Ozempic, which was adapted from lizard spit—yes, lizard spit—Mounjaro was designed from the ground up by Eli Lilly to be a dual receptor agonist.
- Mounjaro was designed from the ground up by Eli Lilly to be a dual receptor agonist.
Mounjaro was designed from the ground up by Eli Lilly to be a dual receptor agonist.
Warning over prescription drugs causing impulsive behaviour | BBC News
- Brandon has Tourette's syndrome and had only just started secondary school when he was prescribed aripiprazole, a separate drug that's known as a partial dopamine agonist but also causes impulsive behaviour.
Brandon has Tourette's syndrome and had only just started secondary school when he was prescribed aripiprazole, a separate drug that's known as a partial dopamine agonist but also causes impulsive behaviour.
- Brandon has Tourette syndrome and had only just started secondary school when he was prescribed aripiprazole, a separate drug that's known as a partial dopamine agonist but also causes impulsive behavior.
Brandon has Tourette syndrome and had only just started secondary school when he was prescribed aripiprazole, a separate drug that's known as a partial dopamine agonist but also causes impulsive behavior.
Can This Drug Make You Thin? 🏃♂️💊
- It's a type of drug called a GLP1 agonist, which mimics the GLP1 hormone in your body.
It's a type of drug called a GLP1 agonist, which mimics the GLP1 hormone in your body.
- It's a type of drug called a GLP-1 agonist, which mimics the GLP-1 hormone in your body.
It's a type of drug called a GLP-1 agonist, which mimics the GLP-1 hormone in your body.
16) Pharmacology of vasoactive therapies used in low-output heart failure and cardiogenic shock.
- Um, sort of an archetype agonist like phenylephrine is a clear squeeze-only alpha-1 agent.
Um, sort of an archetype agonist like phenylephrine is a clear squeeze-only alpha-1 agent.
- Um, sort of an archetype agonist like phenylephrine is a clear squeeze-only alpha-1 agent.
Um, sort of an archetype agonist like phenylephrine is a clear squeeze-only alpha-1 agent.
The New Addiction Treatment We Found By Mistake
- In mice, rats, and even non-human primates, giving an animal a GLP-1 agonist reduces how much alcohol they drink and decreases the rewarding effects of drinking alcohol.
In mice, rats, and even non-human primates, giving an animal a GLP-1 agonist reduces how much alcohol they drink and decreases the rewarding effects of drinking alcohol.
- One of those few human studies found that one GLP-1 receptor agonist reduced alcohol use in patients who were obese, but not in patients who weren't.
One of those few human studies found that one GLP-1 receptor agonist reduced alcohol use in patients who were obese, but not in patients who weren't.
The deadly drug everyone is taking
- Glucagon-like peptide 1, or GLP-1, is a receptor agonist that many people have likely heard of.
Glucagon-like peptide 1, or GLP-1, is a receptor agonist that many people have likely heard of.
PBS News Hour full episode, June 19, 2026
- But the data really support the idea that weight loss through a GLP-1 receptor agonist can not only help to prevent many of the obesity-related cancers, but
But the data really support the idea that weight loss through a GLP-1 receptor agonist can not only help to prevent many of the obesity-related cancers, but
- So, it's not surprising that, when we look at these large observational data sets, a GLP-1 receptor agonist, which can typically induce 15 to 20 percent or even greater weight loss, similar to what bariatric surgeries do, that these drugs can also reduce the risk of cancer.
So, it's not surprising that, when we look at these large observational data sets, a GLP-1 receptor agonist, which can typically induce 15 to 20 percent or even greater weight loss, similar to what bariatric surgeries do, that these drugs can also reduce the risk of cancer.
Research shows weight-loss drugs may also reduce cancer risk
- But the data really support the idea that weight loss through a GLP-1 receptor agonist can not only help to prevent many of the obesity-related cancers, but
But the data really support the idea that weight loss through a GLP-1 receptor agonist can not only help to prevent many of the obesity-related cancers, but
- So, it's not surprising that, when we look at these large observational data sets, a GLP-1 receptor agonist, which can typically induce 15 to 20 percent or even greater weight loss, similar to what bariatric surgeries do, that these drugs can also reduce the risk of cancer.
So, it's not surprising that, when we look at these large observational data sets, a GLP-1 receptor agonist, which can typically induce 15 to 20 percent or even greater weight loss, similar to what bariatric surgeries do, that these drugs can also reduce the risk of cancer.